Pharmaceuticals, Biotechnology and Life Sciences
Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.
Neurocrine Biosciences, published a new analysis of Ingrezza (valbenazine) capsules, in the Journal of Affective Disorders, pointing out improvement in tardive dyskinesia (TD) symptoms in patients with primary mood disorders, with no clinically meaningful changes to psychiatric stability.
The U.S. Food and Drug Administration has approved Neurocrine Biosciences’s Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia.
On Thursday, March 16, 2017, the Dow Jones Industrial Average and the S&P 500 edged 0.07% and 0.16% lower, respectively, at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally higher by 0.01%. Five out of nine sectors ended Thursday’s trading session in bullish territories. Taking into consideration yesterday’s market sentiment, Stock-Callers.com assessed the several drugs – generic equities on Friday.